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Abstract
Background: Pancreatic cancer is recognized as one of the most fatal tumors due to its aggressiveness and resistance
to therapy. Statins were previously shown to inhibit the proliferation of cancer cells via various signaling pathways. In
healthy tissues, statins activate the heme oxygenase pathway, nevertheless the role of heme oxygenase in pancreatic
cancer is still controversial. The aim of this study was to evaluate, whether anti-proliferative effects of statins in
pancreatic cancer cells are mediated via the heme oxygenase pathway.
Methods: In vitro effects of various statins and hemin, a heme oxygenase inducer, on cell proliferation were evaluated
in PA-TU-8902, MiaPaCa-2 and BxPC-3 human pancreatic cancer cell lines. The effect of statins on heme oxygenase
activity was assessed and heme oxygenase-silenced cells were used for pancreatic cancer cell proliferation studies. Cell
death rate and reactive oxygen species production were measured in PA-TU-8902 cells, followed by evaluation of the
effect of cerivastatin on GFP-K-Ras trafficking and expression of markers of invasiveness, osteopontin (SPP1) and SOX2.
Results: While simvastatin and cerivastatin displayed major anti-proliferative properties in all cell lines tested, pravastatin
did not affect the cell growth at all. Strong anti-proliferative effect was observed also for hemin. Co-treatment of
cerivastatin and hemin increased anti-proliferative potential of these agents, via increased production of reactive oxygen
species and cell death compared to individual treatment. Heme oxygenase silencing did not prevent pancreatic cancer
cells from the tumor-suppressive effect of cerivastatin or hemin. Cerivastatin, but not pravastatin, protected Ras protein
from trafficking to the cell membrane and significantly reduced expressions of SPP1 (p < 0.05) and SOX2 (p < 0.01).
Conclusions: Anti-proliferative effects of statins and hemin on human pancreatic cancer cell lines do not seem to be
related to the heme oxygenase pathway. While hemin triggers reactive oxygen species-induced cell death, cerivastatin
targets Ras protein trafficking and affects markers of invasiveness.
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Background
Pancreatic cancer has a very poor prognosis mainly due
to late diagnosis of already advanced tumors, often with
metastases to distant organs. Since high resistance to
therapy aggravates the treatment outcomes, new efficient
treatment modalities and therapy targets are under
investigation.
Statins, competitive inhibitors of 3-hydroxyl-methylglutaryl
coenzyme A (HMG CoA) reductase, are widely used for
treatment of hypercholesterolemia. However, their thera-
peutic role surpasses the cholesterol lowering capacity, util-
izing anti-inflammatory, anti-oxidant and anti-thrombotic
actions [1]. Additionally, several studies suggested the anti-
proliferative role of statins in various cancer cell lines, in-
cluding lung [2], colorectal [3] and pancreatic cancer [4–7].
These effects could be partly mediated by the depletion of
several important intermediates of cholesterol biosynthesis
involved in posttranslational protein prenylation. This
process is especially important for modification of small
GTPases, such as Ras [8, 9], which is essential for their
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translocation from cytoplasm to the cell membrane, affect-
ing thus their cell proliferating activities [1] via targeting
several important signal transduction pathways [10–12].
The association of activation mutations in the K-ras onco-
gene with pancreatic cancer is well established, being found
in more than 90 % of human pancreatic cancers [13]. We
previously reported that most statins protect green fluores-
cent protein (GFP)-K-Ras from its anchoring to the cell
membrane, affecting the signaling pathways and leading to
suppression of cancer cell growth in pancreatic cancer cells
in vitro [4].
Heme oxygenase (HMOX), the key enzyme in heme
metabolism, catalyzes the degradation of heme to equi-
molar quantities of CO, free iron and biliverdin, which is
subsequently converted to bilirubin [14]. While the in-
duction of HMOX1 represents a key biological process in
adaptive response to cellular stress and displays anti-
inflammatory, anti-apoptotic and anti-oxidative actions
[14–17], its role in cell proliferation and tumor progres-
sion is still controversial [18, 19]. Some studies suggested
that statins can upregulate the HMOX gene expression in
a cell- and species-specific manner [20–24], and they exert
some of their protective effects via this pathway [21].
However, the upregulation of HMOX1 in pancreatic can-
cer cells was previously connected to worsened treatment
outcome [25].
The aim of this study was to evaluate anti-proliferative
effects of statins with respect to their possible role in
modulation of HMOX pathway in pancreatic cancer in
vitro. Hemin, a strong HMOX1 inducer [26], was used a
control compound. Further, we investigated the effects
of cerivastatin on targeting the GFP-K-Ras protein traf-
ficking, as well as the regulation of invasiveness of pan-
creatic adenocarcinoma cells in vitro, elucidating the




Cerivastatin, pravastatin and fluvastatin were purchased
from LKT Laboratories, Inc (USA), lovastatin and simva-
statin from Santa Cruz Biotechnology (Dallas, TX, USA).
Bovine serum albumin (BSA), hemin, reduced nicotina-
mide adenine dinucleotide (NADPH), sulfosalicylic acid,
Dulbecco’s Modified Essential Media (DMEM), and
RPMI-1640 were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Fetal bovine serum (FBS) and L-
glutamine (L-Glu) were purchased from Biosera (Boussens,
France), 15-deoxy-Δ-12,14-prostaglandin J2 (PGJ2) was
purchased from Merck (Darmstadt, Germany).
Cell culture
For cell culture studies, the following pancreatic cancer
cell lines were used: PA-TU-8902 (DSMZ, Braunschweig,
Germany), MiaPaCa-2 and BxPC-3 (ATCC, Manassas,
VA, USA). All cell lines were maintained and grown in a
humidified atmosphere containing 5 % CO2 at 37 °C. PA-
TU-8902 and MiaPaCa-2 were cultured in DMEM sup-
plemented with 10 % FBS, antibiotics and 1 % L-Glu,
BxPC-3 in RPMI-1640 supplemented with 10 % FBS, anti-
biotics and 2 % L-Glu. For all experiments, medium with
reduced content of FBS to the final concentration of 0.5 %
was used. All statins in the study were used at 12 μM (cor-
responding to IC50 of simvastatin for MiaPaCa-2 cells
after 24 h incubation [4]) diluted in methanol (vehicle)
and hemin (methemalbumin) was prepared as previously
described and used in the final concentration of 30 μM
(pH = 7.4) [26].
Ethical approval for work on cell lines was not re-
quired by our Institution.
HMOX RNA interference (RNAi)
Pancreatic cancer cells were transfected with 10 pmol of
HMOX1 esiRNA and 10 pmol of HMOX2 esiRNA
(Sigma-Aldrich) per 5 x 103 seeded cells using the Lipofec-
tamine RNAiMAX reagent (Life Technologies, Carlsbad,
CA, USA) for 24 h in ATB-free DMEM medium. The
esiRNA Universal control was used as negative control in
all experiments. Data were expressed as % of esiRNA
Universal control (Sigma-Aldrich).
Cell proliferation assay
For the cell proliferation assay, cells were seeded into 96
well (5–12.5 x 104 cells per ml according to the cell line)
and kept at 37 °C and 5 % CO2. After 24 h, cells were
treated with statins or/and hemin, followed by the MTT
test (Sigma-Aldrich) as a general cell proliferation assay.
As we experienced difficulties with hemin-treated sam-
ples using MTT test due to interfering effects of hemin,
we further used the more sensitive CellTiter-Glo Lumi-
nescent Cell Viability Assay (Promega, Fichburg, WI,
USA). Both tests were used according to the manufac-
turer's instructions. Results were expressed as % of
controls.
HMOX activity measurement
Cells in plates were treated with statins and hemin. After
12 h, cells were washed twice with ice-cold phosphate
buffer and finally collected into freshly added phosphate
buffer and centrifuged. The pellet was resuspended in
150 μl of 0.1 M potassium phosphate buffer (pH = 7.4)
and sonicated with an ultrasonic cell disruptor (Model
XL2000, Misonics, Farmingdale, NY, USA). The protein
concentration was assessed using the DC™ Protein Assay
(Bio-Rad Laboratories, Hercules, CA, USA) according to
the manufacturer's instruction. A total of 0.15 mg of
protein was incubated for 15 min at 37 °C in CO-free
septum-sealed vials containing 20 μl of 4.5 mM NADPH
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as previously described [27]. The amount of CO ge-
nerated by HMOX activity was quantified by gas chroma-
tography with a reduction gas analyzer (Peak Laboratories
LLC, Mountain View, CA, USA) and calculated as pmol
CO/h/mg protein. Five μM PGJ2 was used as a positive
control of heme regulation. Results were expressed as % of
control.
Western blot analyses
For protein expression analyses, cells were transfected
with esiRNA universal control or esiRNA HMOX1/2 as
mentioned previously. After 24 h, cells were treated with
30 μm hemin for 20 h. Hemin treatment was used to up-
regulate HMOX1 protein expression to cumulate detect-
able levels of HMOX1 protein. Thirty μg of total protein
were separated on 12 % polyacrylamide gel and then
transferred to nitrocellulose membrane (Bio-Rad La-
boratories). After blocking in Tween-PBS with 5 % milk
(Sigma-Aldrich) for at least 1 h, membranes were incu-
bated with HMOX1 antibody (1:1000; Thermo Fisher,
Rockford, IL, USA), or β-actin (1:1000; Cell Signaling
Technology, Danvers, MA, USA) overnight at 4 °C. After
washing, membranes were incubated with anti-mouse
IgG-HRP (Abcam, Cambridge, UK) for 1 h. Immuno-
complexes on the membranes were visualized with ECL
Western Blotting Detection Reagents (Cell Signaling
Technology).
Real-time PCR analysis of mRNA
HMOX1 expression
Cells grown in plates were treated with statins, hemin or
PGJ2. After 4 h, they were washed twice with ice-cold
PBS and collected in the lysis buffer. Total cell RNA was
isolated using Perfect Pure RNA Cultured Cell Kit
(5Prime, Gaithersburg, MD, USA) and cDNA was gener-
ated using High Capacity RNA-to-cDNA Master Mix
(Life Technologies) according to the manufacturer’s in-
structions. Real-time PCR for HMOX1 (OMIM *141250)
and HMOX2 (OMIM *141251) was performed using the
SYBR master mix (Life Technologies) according to the
manufacturer’s instructions with optimized primers
(Generi Biotech, Hradec Králové, Czech Republic). Re-
sults were calculated using the comparative Ct method
with HPRT as a house-keeping gene and were expressed
as % of control.
Markers of invasiveness
Cells were treated for 12, 24 and 48 h with individual sta-
tins. Total RNA was collected and cDNA generated as
mentioned above. For real-time qPCR, cDNA correspond-
ing to 10 ng of starting total RNA was diluted with water
in 3.6 μl; 0.2 μl of the combined 10 μM forward and re-
verse primers were added and, finally, 3.8 μl of 2x iTaq
Universal SYBR Green Supermix (Bio-Rad Laboratories)
was added. The reaction was carried out using the Eco
real-time PCR system (Illumina, San Diego, CA, USA)
using three-step PCR. The relative mRNA expression
levels of osteopontin (secreted phosphoprotein 1, SPP1,
OMIM*166490) and sex-determining region Y-related
HMG box 2 (SOX2, OMIM*184429) were calculated using
the comparative Ct (ΔΔCt) method, with ribosomal
phosphoprotein (P0, OMIM*180510) as a reference gene.
Sequences of primers used for real-time PCR: SPP1
forward, AGA CCT GAC ATC CAG TAC CCT, reverse
- CAA CGG GGA TGG CCT TGT AT; SOX2 forward -
AGG ACC AGC TGG GCT ACC CG, reverse - GCC
AAG AGC CAT GCC AGG GG.
Apoptosis evaluation
Apoptosis was quantified using the annexin V-FITC
method, which detects phosphatidyl serine externalized
in the early phases of apoptosis, in combination with
propidium iodide (PI) staining. After exposure to ceri-
vastatin and/or hemin, floating and attached cells were
collected, washed with PBS, re-suspended in 100 μl
binding buffer and incubated for 20 min at room
temperature with 0.3 μl annexin V-FITC (Apronex,
Vestec, Czech Republic). PI (10 μg/ml) was added dir-
ectly before flow cytometry analysis (BD FASC Calibur,
BD, Franklin Lakes, NJ, USA). Annexin V positive (An+)
and PI negative (PI-) are cells in early apoptosis, An +
and/or PI positive (PI+) are cells in late apoptosis or
post-apoptotic necrosis.
Reactive oxygen species (ROS) generation
For assessment of ROS generation, dichlordihydrofluor-
escein diacetate (H2DCFDA) (Life Technologies) was
used. After treatment, cells were washed and exposed to
10 μM H2DCFDA in 37 °C for 20 min. Cells were then
washed, lysed and the fluorescent signal at 492/520 (Ex/
Em) was evaluated in 100 μl aliquots. Total fluorescence
was related to protein concentration. Results were
expressed as % of control.
Ras protein translocation assay
PA-TU-8902 cells were seeded in dishes with glass bottom
6 h before transfection by pEGFP-KrasWT (GFP – green
fluorescent protein, WT-wild type) plasmid prepared as
described previously [4]. Transfection was carried out
using FuGene HD according to the manufacturer’s in-
structions. Cerivastatin (12 μM), pravastatin (12 μM) and
hemin (30 μM) were added 12 h post transfection and the
cells incubated with the agents for 24 h. Intracellular
localization of the GFP-K-Ras protein was visualized by
confocal microscopy, using a spinning disk confocal
microscope (Olympus, Tokyo, Japan; Andor, Belfast, UK)
equipped with solid state laser (488 nm for continual exci-
tation). Emission was collected through a single-band
Vanova et al. BMC Cancer  (2016) 16:309 Page 3 of 11
filter (BrightLine® FF01-525 nm, Semrock Inc., NY, USA).
The images were obtained and analyzed with the iQ2 soft-
ware (Andor).
Statistical analysis
All data were expressed as mean ± SD. For normally dis-
tributed datasets, one-way ANOVA with post-hoc
Holm-Sidak test for multiple comparisons was used for
analysis. For non-normally distributed data and small
datasets (n ≤ 6), Mann–Whitney rank sum test and
Kruskal-Wallis ANOVA with Dunn’s test for multiple
comparisons were used. P-values less than 0.05 were
considered statistically significant.
All datasets of the results discussed in the manuscript
are available on request.
Results
Statins exert different anti-proliferative on pancreatic can-
cer cell lines
The inhibitory effects of individual statins on prolifera-
tion were assessed using cultured human pancreatic can-
cer cells. Except pravastatin, all selected statins, used at
12 μM, showed significant anti-proliferative effects on
growth of tested cancer cells after 48 h of treatment
(Fig. 1). Various statins exhibited different anti-
proliferative potential covering the spectrum from the
most effective cerivastatin and simvastatin, followed by
fluvastatin and lovastatin, to ineffective pravastatin. Add-
itionally, we observed significantly different sensitivity
for particular pancreatic cancer cell lines. The most sen-
sitive cell line was MiaPaCa-2, bearing activating K-ras
mutation in codon 12 (34G > T) [28]. By contrast, the
other cell line PA-TU-8902 with another activating mu-
tations in K-ras oncogene in codon 12 (35G > T) [29] re-
vealed to be more resistant to statin treatment. BxPC-3
cells, featuring wild-type K-ras oncogene and overex-
pressing cyclo-oxygenase-2 [28], were slightly more sen-
sitive than PA-TU-8902 cells to several statins and
significantly more resistant to statin treatment than
MiaPaCa-2 cells (Fig. 1). The most efficient statin was
cerivastatin, which decreased cell proliferation as com-
pared to untreated controls to 51 ± 8 %, 61 ± 10 %, and
14 ± 2 % following 48-h treatment of PA-TU-8902,
BxPC-3 and MiaPaCa-2 cells, respectively, with p <
0.0001 for all comparisons.
Statins do not affect HMOX expression and activity in
human pancreatic cancer cells
To find out whether statins regulate HMOX activity in
selected pancreatic cell lines in vitro, and whether this
mechanism could possibly contribute to their anti-
proliferative properties, we treated pancreatic cancer
cells with individual statins for 12 h. However, none of
the statins affected HMOX activity in any of the studied
cell lines (Fig. 2a). There was no difference in basal
HMOX activities between PA-TU-8902, MiaPaCa-2 and
BxPC-3 cells (0.79 ± 0.12 vs. 0.89 ± 0.19 vs. 0.90 ±
0.14 nmol CO/h/mg protein, respectively, p > 0.05). For
detailed analysis, we selected the most resistant cell line,
PA-TU-8902, and tested the effect of cerivastatin, the
most efficient statin (Fig. 1). Hemin and PGJ2, used as
positive controls, strongly increased both expression and
Fig. 1 Anti-proliferative effect of statins on pancreatic cancer cells.
The effect of simvastatin, cerivastatin, fluvastatin, lovastatin and
pravastatin on cell proliferation was measured using MTT test in a)
PA-TU-8902, b) MiaPaCa-2, and c) BxPC-3 after 48 h of treatment.
Statin concentration = 12 μM *p < 0.01, **p < 0.0001 vs. control cells.
CON, control cells; SIM, simvastatin; CER, cerivastatin; FLU, fluvastatin;
LOV, lovastatin; PRA, pravastatin
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activity of HMOX after 4 and 12 h, respectively. Cerivas-
tatin affected neither HMOX1 expression nor HMOX
activity in PA-TU-8902 cells. Addition of cerivastatin to
hemin had no impact on HMOX induction by hemin it-
self (Fig. 2b, c).
Hemin augments anti-proliferative effects of selected sta-
tins in pancreatic cancer cells
While using hemin primarily as a HMOX inducer,
we unexpectedly noticed the decrease in proliferation
in hemin-treated cells. Thus we further focused on
more detailed analysis of possible anti-proliferative
effects of hemin on the growth of pancreatic cancer
cell lines. Indeed, we found a significant effect of
30 μM hemin on cell proliferation in all used cell
lines after 48 h (Fig. 3), which was dose-dependent
(data not shown). Hemin treatment decreased cell
proliferation to 62 ± 5 %, 51 ± 3 %, and 38 ± 8 % in
PA-TU-8902, BxPC-3 and MiaPaCa-2 cancer cells,
respectively, with p < 0.0001 for all comparisons.
Furthermore, we observed enhancement of anti-
proliferative effects of statins by hemin, documented
as decreased cell proliferation after 48 h of co-
treatment (Fig. 3).
Suppression of HMOX gene expression does not diminish
anti-proliferative effects of cerivastatin and hemin
Recently it has been suggested, that statin treatment
promotes post-transcriptional regulation of the HMOX1
protein rather than affecting HMOX1 gene expression in
human endothelial cells [30]. To further resolve if
HMOX is involved in anti-proliferative effects of statins
on human pancreatic cancer, we silenced HMOX1 and
HMOX2 in pancreatic cancer cells with esiRNA and
assessed cell proliferation after 48 h of exposure to ceri-
vastatin and hemin. In all cancer cell lines, HMOX1 and
HMOX2 were successfully silenced as demonstrated in
Fig. 4. Significant anti-proliferative effect of cerivastatin
was observed after 48 h in both silenced and cells trans-
fected with esiRNA universal control. Interestingly, cell
growth was affected by the silencing itself implying the
important role of HMOX in the cell survival.
Fig. 2 The effect of statins on activity and expression of HMOX in pancreatic cancer cells a) HMOX activity was measured in PA-TU-8902,
MiaPaCa-2 and BxPC-3 pancreatic cancer cell lines after 12 h of statin treatment (12 μM). b HMOX activity after 12 h of treatment were measured in
PA-TU-8902, and c) HMOX1 mRNA after 4 h of treatment. Hemin (30 μM) and PGJ2 (5 μM) served as positive controls for HMOX1 induction ability.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. control cells CON, control cells; SIM, simvastatin; CER, cerivastatin; FLU, fluvastatin; LOV, lovastatin;
PRA, pravastatin; PGJ2, 15-deoxy-Δ-12,14-prostaglandin J2
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Furthermore, hemin treatment effectively decreased cell
proliferation in controls, as well as HMOX-silenced
cells, and addition of hemin to cerivastatin endorsed
the anti-proliferative effect of cerivastatin (Fig. 5), in-
dicating that these processes are not mediated by
HMOX.
Hemin and cerivastatin enhance ROS production and cell
death in vitro
To evaluate the possible mechanism of cell growth sup-
pression, we assessed apoptotic effects of hemin and cer-
ivastatin in PA-TU-8902 and BxPC-3 cells. While there
was no notable effect of hemin on early apoptosis, we
found a significant increase in the total cell death rate
including late apoptotic and post-apoptotic necrotic cells
at 48 h of treatment. In fact, the major increase in cell
death was noticed within the first 14 h of treatment with
no significant elevation in the later phase (data not
shown). Cerivastatin treatment caused a significant in-
crease in all phases of apoptosis including the early
phase (Fig. 6a, b). Since apoptotic pathways may be
linked to ROS production, we assessed total ROS
production after 48 h of treatment, and observed a
substantial increase in ROS concentration in re-
sponse to cerivastatin (314 ± 53 % and 173 ± 22 %
for PA-TU-8902 and BxPC-3, respectively, p < 0.05
for both comparisons) and even much higher in-
crease due to hemin (1394 ± 372 % and 441 ±
152 % for PA-TU-8902 and BxPC-3, respectively, p
< 0.01 for both comparisons), with a further addi-
tive effect of both compounds (3615 ± 1043 % and
795 ± 72 % for PA-TU-8902 and BxPC-3, respect-
ively, p < 0.01 for both comparisons) (Fig. 6b, c, d).
Interestingly, the rate of cell death and ROS pro-
duction differed between both cell lines suggesting
cell death was not in direct relationship with ROS
production.
Cerivastatin prevents K-Ras protein trafficking in PA-
TU-8902
Since we previously reported that pravastatin is the
only statin not being able to prevent GFP-K-Ras pro-
tein from accumulation on the cell membrane in
MiaPaCa-2 cells [4], we decided to detect the effect
of cerivastatin and pravastatin on localization of GFP-
K-Ras protein also in the thoroughly tested PA-TU-
8902 cell line. As demonstrated in Fig. 7, cerivastatin
efficiently inhibited GFP-K-Ras protein trafficking
from cytoplasm to the cell membrane, while prava-
statin was inefficient. Hemin itself, or in combination
with statins did not influence GFP-K-Ras trafficking
at all (data not shown).
Fig. 3 Effects of hemin and statins on proliferation of pancreatic
cancer cells. The effects of hemin (30 μM), cerivastatin (12 μM),
fluvastatin (12 μM) and pravastatin (12 μM) and their combination
with hemin were measured in a) PA-TU-8902, b) MiaPaCa-2, and c)
BxPC-3 after 48 h of treatment using CellTiter-Glo test. *p < 0.01, **p
< 0.0001 vs. control cells, #p < 0.01 vs. hemin CON, control cells; CER,
cerivastatin; FLU, fluvastatin; PRA, pravastatin
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Cerivastatin downregulates selected markers of
invasiveness
Among others, poor prognosis of pancreatic cancer is
due to early metastases and high invasiveness of this
type of tumor. To determine whether cerivastatin
treatment affects invasiveness of pancreatic cancer
cells, we assessed selected markers previously re-
ported to be associated with metastatic processes in
pancreatic cancer, i.e. SPP1 and SOX2. In PA-TU-
8902 cells, SPP1 mRNA expression was significantly
suppressed to 59 ± 13 % (p < 0.01) at 12 h of treat-
ment with persisting effect of up to 48 h (17 ± 8 %
and 40 ± 20 % at 24 and 48 h, respectively; p < 0.05;
Fig. 8a). Similarly, SOX2 mRNA expression decreased
to 25 ± 9 % (p < 0.01) in 12 h with persisting effect to
48 h of treatment (24 ± 4 % and 61 ± 13 % at 24 and
48 h; respectively; p < 0.01, Fig. 8b).
Discussion
Only little progress has been achieved in the treatment
of pancreatic cancer over recent decades [31]. Among
multiple tested experimental drugs, statins were shown
to display anticancer effects in this malignant disease
[32, 33]. In our study, we investigated a possible relation
between statins and the HMOX pathway that play a role
in pancreatic carcinogenesis [25].
Even though HMOX upregulation is associated with
beneficial effects for cells, its role in carcinogenesis re-
mains controversial [19]. HMOX seems to negatively
affect the outcome of treatment [25] and enhance the
aggressiveness and progression of pancreatic cancer [34].
Moreover, pancreatic cancer cells were shown to overex-
press HMOX1 compared to normal pancreatic tissue
[25, 34]. On the other hand, statins have been previously
shown to upregulate HMOX gene expression, and some
of their protective effects are believed to be mediated via
this pathway [24]. Together with these HMOX1-
inducing effects, statins simultaneously inhibit pancre-
atic cancer cell proliferation [4]. In this study, we
assessed the overall relationship of particular statins to
HMOX regulation in pancreatic cancer cells. We were
able to demonstrate no effect of the tested statins on
HMOX activity in selected human pancreatic cancer cell
lines, despite their remarkable anti-proliferative effects.
Fig. 4 Effect of esiRNA HMOX1/2 transfection on HMOX expression in pancreatic cancer cells. PA-TU-8902, MiaPaCa-2 and BxPC-3 cells were transfected
with esiRNA for HMOX1/HMOX2 or universal control esiRNA and mRNA expression of a) HMOX1 and b) HMOX2 was measured after 24 h. c HMOX1
protein expression was measured in cells treated with 30 μM hemin for 20 h. Hemin treatment was used to upregulate HMOX1 protein expression to
cumulate detectable levels of HMOX1 protein. *p < 0.05, **p < 0.01, ****p < 0.0001 vs. esiRNA control cells
Fig. 5 Effect of statin and hemin on proliferation of HMOX-silenced pancreatic cancer cells. Both HMOX1 and HMOX2 were silenced with esiRNA in
a) PA-TU-8902, b) Mia-PaCa-2, and c) BXpC-3 pancreatic cancer cells, and the effect of cerivastatin (12 μM) and hemin (30 μM) on cell proliferation was
measured by CellTiter-Glo test after 48 h of treatment. *p < 0.05, **p < 0.01, ***p < 0.0001 vs. control cells, #p < 0.01 vs. esiRNA control cells. CON, control
cells; CER, cerivastatin
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Moreover, suppression of proliferation by cerivastatin
treatment persisted also in HMOX1- and HMOX2-si-
lenced cells, indicating that these effects did not depend
on the HMOX pathway. Importantly, we noted that
HMOX silencing decreased the cell growth, implying
an important role of HMOX in pancreatic cancer cell
survival. This is in agreement with previous studies
[25, 34].
To test a possible effect of HMOX on pancreatic
carcinogenesis, hemin, a potent HMOX1 inducer [26],
was used in further experiments. To our surprise, a
significant decrease in cell proliferation was observed
in all tested pancreatic cancer cell lines, despite
HMOX induction. Moreover, co-treatment of the cells
with hemin and statins increased the anti-proliferative
effect of the latter. This is most likely due to hemin-
mediated HMOX-independent mechanisms that play a
role in cell proliferation and survival. Indeed, we
found significant hemin-induced increase in apoptosis,
corresponding to considerable increase in ROS pro-
duction. The same cell growth inhibitory effects were
observed even in HMOX-silenced cells, further sug-
gesting the independence of hemin bioactivity on the
HMOX pathway. Thus, neither statins- nor hemin-
dependent suppression of proliferation involved the
HMOX system; further, induction of HMOX by he-
min did not prevent this response of pancreatic can-
cer cells to the agents. Nevertheless, our data from
HMOX1/2 silencing support pro-carcinogenic role of
HMOX in pancreatic cancer, consistent with previous
clinical observation [25].
Despite the fact that hemin was suggested to con-
tribute to increased colon cancer incidence in red
meat eaters [35], other studies shown clear antican-
cer effects of this compound [36] supporting our
findings.
Similarly as in our previous study [4] and as dis-
cussed recently [37], we observed remarkable differ-
ences in anti-proliferative effects of individual statins,
which were dependent also on the cell line used. Both
MiaPaCa-2 and PA-TU-8902 cells carry the K-ras mu-
tation in codon 12 [28, 29]. Hamidi and colleagues
found that in pancreatic cancer cells, this mutation
makes the cells more sensitive to inhibitors of MEK1/
2, which is a kinase activated by K-Ras [29]. To ex-
tend our study to pancreatic cancer cells lacking the
K-ras mutation, we also used BxPC-3 cells carrying a
wild-type K-ras proto-oncogene and overexpressing
cyclooxygenase [28]. As expected, MiaPaCa-2 cells
were the most susceptible and PA-TU-8902 were the
Fig. 6 Effect of hemin and cerivastatin on ROS production and apoptosis in PA-TU-8902 and BxPC-3 pancreatic cancer cells. The effects of hemin
(30 μM), cerivastatin (12 μM) and their combination on apoptosis in a) PA-TU-8902 and b) BxPC-3, and ROS production in c) PA-TU-8902 and d)
BxPC-3 were measured after 48 h of treatment. An+/PI- represents cells in early apoptosis, An + and/or PI+ represents cells in late apoptosis or
already dead. *p < 0.05, **p < 0.01, ***p < 0.0001 vs. control cells. CON, control cells; CER, cerivastatin
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most resistant cells to statin treatment in our
experiments.
All the statins except pravastatin exerted remarkable
growth inhibitory activity in all tested pancreatic cancer
cell lines with cerivastatin being the most efficient of
these agents. One of the mechanisms possibly involved
in anti-carcinogenic effect of cerivastatin might be in-
creased production of ROS, similarly as demonstrated in
lymphoma cells [38]. Interestingly, this phenomenon
was much more pronounced in hemin-treated cells and,
in particular, in cells exposed to hemin together with
cerivastatin.
The K-ras pathway is another possible target of sta-
tins. In fact, Gbelcova and colleagues demonstrated
that statins, except for pravastatin, prevented the
GFP-K-Ras protein from its cell membrane
localization in MiaPaCa-2 cells [4]. We performed a
similar experiment in PA-TU-8902 pancreatic cancer
cells, and found that while pravastatin did not affect
translocation of the K-Ras protein to the cell mem-
brane, cerivastatin significantly prevented GFP-K-Ras
from membrane localization. The K-Ras signaling
pathway is essential for metastatic lesion formation
and tumor invasiveness [39]. Interestingly, cerivastatin
but not pravastatin treatment of PA-TU-8902 cells
significantly decreased the expression of SPP1 and
SOX2, factors with important role in cancer metasta-
sis and aggressiveness [40, 41]. Meta-analysis of 11
studies revealed that patients with pancreatic cancer
have elevated serum levels of SPP1 [42]. Similarly,
SOX2 over-expression promotes self-renewal and de-
differentiation of pancreatic cancer cells [43]. In our
experiments, both markers were downregulated in
pancreatic cancer cells exposed to cerivastatin, point-
ing to a lowering effect of the statin on the metastatic
potential of the cells.
Conclusion
Our data suggest that anti-proliferative effects of sta-
tins are not mediated via HMOX pathway. Cerivas-
tatin, the most efficient statin in our study, was
capable of inducing several ‘events’ involved in
carcinogenesis, including apoptosis, ROS production
and inhibition of K-Ras trafficking. Hemin treatment
not only substantially decreased cell proliferation
Fig. 7 Effect of hemin and statins on GFP-K-Ras localization in PA-
TU-8902 pancreatic cancer cells. The effect of a) vehicle, b) hemin
(30 μM), c) cerivastatin (12 μM) and d) pravastatin (12 μM) on
localization of GFP-K-Ras was tested in PA-TU-8902 pancreatic cancer
cells transfected with pEGFP-K-RasWT plasmids after 24 h of treat-
ment. CON, control cells; CER, cerivastatin; PRA, pravastatin
Fig. 8 Effect of cerivastatin and pravastatin on selected markers of invasiveness in PA-TU-8902 pancreatic cancer cells. a) Osteopontin (SPP1) and
b) SOX2 mRNA expressions were measured in different time points of treatment with cerivastatin (12 μM) and pravastatin (12 μM). *p < 0.05, **p
< 0.01, ***p < 0.001 vs. control cells. CON, control cells; CER, cerivastatin; PRA, pravastatin
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independently on HMOX induction, but enhanced
anti-proliferative properties of statins in human pan-
creatic cancer cells. Our findings support the role of
statins as agents with potential anti-pancreatic can-
cer activities.
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